West Branch Capital LLC Purchases 2,498 Shares of Eli Lilly and Company $LLY

West Branch Capital LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 43.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 8,233 shares of the company’s stock after acquiring an additional 2,498 shares during the period. Eli Lilly and Company makes up approximately 1.9% of West Branch Capital LLC’s portfolio, making the stock its 15th biggest position. West Branch Capital LLC’s holdings in Eli Lilly and Company were worth $6,418,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Duquesne Family Office LLC grew its holdings in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares during the last quarter. Corient IA LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $570,000. LS Investment Advisors LLC increased its holdings in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after purchasing an additional 40 shares in the last quarter. Cutter Capital Management LP acquired a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $207,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on LLY. UBS Group dropped their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and increased their price objective for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $939.61.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.4%

Shares of Eli Lilly and Company stock opened at $724.73 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market cap of $685.93 billion, a price-to-earnings ratio of 47.37, a P/E/G ratio of 1.01 and a beta of 0.47. The stock has a 50-day simple moving average of $734.15 and a 200-day simple moving average of $766.82. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.